FDA approves another at-home COVID-19 test

The FDA May 16 granted emergency use authorization to a second COVID-19 diagnostic test that allows patients to collect samples using nasal swabs. 

Advertisement

The tests are made by Everlywell, a home health testing company based in Austin, Texas. 

People must take an online screening survey before getting the test to determine whether they meet federal testing guidelines. After the sample is collected, tests can be sent to either Fulgent Therapeutics or Assurance Scientific Laboratories, and Everlywell said it plans to partner with more labs. 

An Everlywell spokesperson told The New York Times that the time between ordering a test and getting test results should be three to five days. 

The tests cost $135 each and will be available later this month. 

The FDA has also granted emergency use authorization to a nasal swab test from LabCorp and a saliva-based test from Rutgers University. 

More articles on supply chain:
FEMA terminates $55M contract with Panthera to produce N95 masks
LabCorp, Quest expand COVID-19 testing
Pandemic spurs collaboration between rival hospitals

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.